FDA Regulatory Control of the Drug Development Process and Investigator Responsibility in the Process April 26, 2013

This training will review the clinical trial investigator's role in the drug development process and show how you can ensure that clinical studies are carried out in compliance with FDA's regulatory expectations.

Why Should You Attend:

There is an increasing frequency of real-time FDA Audits of trials and it seems that no one is well prepared. It is the obligation of the major players in the drug development process (the Investigator and the study Sponsor) to be sure studies are carried out correctly so that errors and mistakes are found and corrected by them (CAPA) and not by an FDA Investigator.
In this 90-minute webinar, you will learn how well-controlled and well-conducted clinical trials that follow the Code of Federal Regulations and the Principles of GCP are important to both sponsors and CRO’s / investigator sites. We will discuss how compliance with the Regs and Good Clinical Practice will ensure quality data, speed up the review process, and decreases the costs.

Areas Covered in the Seminar:

- The Investigators role in the clinical research process, the IC process..
- Know how the Regs define the many terms describing Adverse Events
- Why the investigator files the signed and dated protocol?
- What is the legal language of the FDA form 1572 or Device equivalent?
- Why is Financial Disclosure information important?
- What is the history of the drug / device regulations?

Official Website: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702784?channel=yahooevent